Bottom line
Is SHSCX a good fund? The bottom line
SHSCX is the Investor C share class of Blackrock Health Sciences Opportunities Portfolio, a managed health care sector mutual fund from BlackRock.
It charges 1.9% — about $190 a year on every $10,000 invested, more expensive than 91% of health care sector funds we track.
It returned +14.1% over one year, +4.8% a year over five years, +8.9% a year over ten (as of Dec 31, 2025, per its prospectus).
With $5.9 billion in net assets and 155 holdings, its largest position is Eli Lilly & Company (12.3%) and the top 10 make up 52% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 78% top-holdings overlap).
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.9%)
- Concentrated: top 10 holdings are 52% of assets
- 12b-1 marketing fee of 1% a year
Updated Nov 19, 2026
What SHSCX invests in
The investment objective of BlackRock Health Sciences Opportunities Portfolio (the Fund), a series of BlackRock Funds SM (the Trust), is to provide long-term growth of capital.
Under normal market conditions, the Fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. Investments in derivatives are counted toward the Funds 80% policy to the extent that they provide investment exposure to the securities included within that policy or to one or more market risk factors associated with such securities. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. Health sciences and related industries can include, but are not limited to, businesses involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services, companies engaged in biotechnology and medical research and development, companies that may design…
From the fund's prospectus (filed Sep 25, 2026).
SHSCX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| SHSCX | +14.1% | +4.8% | +8.9% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What SHSCX costs
On a $10,000 investment, SHSCX's 1.9% expense ratio costs about $190 a year. The prospectus estimates $2,016 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
SHSCX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Company LLY | 12.29% |
| 2 | Johnson & Johnson JNJ | 8.77% |
| 3 | Unitedhealth Group Inc UNH | 6.10% |
| 4 | Merck & Company Inc MRK | 4.94% |
| 5 | Gilead Sciences Inc GILD | 4.19% |
| 6 | Abbvie Inc ABBV | 3.94% |
| 7 | Amgen Inc AMGN | 3.37% |
| 8 | Thermo Fisher Scientific Inc TMO | 3.02% |
| 9 | Vertex Pharmaceuticals Inc VRTX | 2.74% |
| 10 | Pfizer Inc PFE | 2.61% |
Source: SEC Form N-PORT, period ended May 29, 2026
The top 10 make up 52% of the fund. See all top 25 holdings and asset mix →
Alternatives to SHSCX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 78% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 78% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 80% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 81% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 55% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 67% | Compare |